Patents by Inventor Benjamin Wang
Benjamin Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11934681Abstract: Managing storage device evacuation that includes a plurality of storage devices, including: detecting, by the storage system, an occurrence of a storage device evacuation event associated with a source storage device within a write group, wherein the write group is a subset of storage devices storing a data set; responsive to detecting the occurrence of the storage device evacuation event, identifying, by the storage system, a target storage device for receiving data stored on the source storage device; and migrating, by the storage system, the data stored on the source storage device to the target storage device.Type: GrantFiled: September 1, 2021Date of Patent: March 19, 2024Assignee: PURE STORAGE, INC.Inventors: Andrew Bernat, John Colgrove, Taher Vohra, Andrew Kleinerman, Xiaohui Wang, Benjamin Scholbrock
-
Publication number: 20240083857Abstract: The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions. The 2-methyl substituted quinazoline compounds of general formula (I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: July 11, 2023Publication date: March 14, 2024Inventors: Lars WORTMANN, Brice SAUTIER, Knut EIS, Hans BRIEM, Niels BOHNKE, Franz VON NUSSBAUM, Roman HILLIG, Benjamin BADER, Jens SCHRODER, Kirstin PETERSEN, Philip LIENAU, Antje Margret WENGNER, Dieter MOOSMAYER, Qiuwen WANG, Hans SCHICK
-
Patent number: 11925281Abstract: Systems and methods for generating clothing recommendations are disclosed herein. In an embodiment, a system for generating a clothing recommendation includes a mirror, a display device, a memory and a processor. The mirror has a first side including a reflective surface. The display device displays a clothing recommendation to the user. The memory stores a wardrobe database including clothing data related to a plurality of items of clothing owned by the user. The processor is programmed to: (i) access a database including a plurality of expert models; (ii) select of one of the plurality of expert models based on a preference of the user; (iii) generate the clothing recommendation using the clothing database in combination with the selected expert model; and (iv) cause the display device to display the clothing recommendation to the user while the user views the first side of the mirror.Type: GrantFiled: January 18, 2023Date of Patent: March 12, 2024Assignee: ACI HOLDINGS LTD.Inventors: Ahmed Farouk Shaaban, Venkat Thandra, Dino Eliopulos, Benjamin Girard, Cole Seabrook, Aria Kim, Manu Varma, Yijun Wang
-
Publication number: 20240075492Abstract: An optical device coating assembly is provided. The optical device coating assembly includes a substrate support operable to retain an optical device substrate. The coating assembly further includes a first actuator connected to the substrate support. The first actuator is configured to rotate the substrate support. The coating assembly includes a holder configured to hold a coating applicator against an edge of the optical device substrate when the optical device substrate is rotated on the substrate support and a second actuator operable to apply a force on the holder in a direction towards the substrate support. The second actuator is a constant force actuator.Type: ApplicationFiled: November 10, 2023Publication date: March 7, 2024Inventors: Kangkang WANG, Yaseer Arafath AHAMED, Yige GAO, Benjamin B. RIORDON, Rami HOURANI, James D. STRASSNER, Ludovic GODET, Thinh NGUYEN
-
Patent number: 11921609Abstract: Systems and methods for data anomaly detection include recommending one or more algorithms from a set of algorithms to process received time series data, wherein the one or more algorithms are recommended based at least in part on a type of workload for processing the received time series data. Assisted parameter tuning is provided for a detected anomaly alert and calibration, and the received time series data is processed based on a user selected algorithm that is parameter tuned.Type: GrantFiled: May 13, 2022Date of Patent: March 5, 2024Assignee: Microsoft Technology Licensing, LLC.Inventors: Roman Batoukov, Richard Wydrowski, Sai Sankalp Arrabolu, Zeqiang Wang, Lech Gudalewicz, Keiji Kanazawa, Benjamin J. Lofton, Thomas W. Potthast, Suren Aghajanyan, Khoa Tran, Jian Zhang
-
Patent number: 11915823Abstract: In some aspects, the described systems and methods provide for validating performance of a model trained on a plurality of annotated pathology images. A pathology image is accessed. Frames are generated using the pathology image. Each frame in the set includes a distinct portion of the pathology image. Reference annotations are received from one or more users. The reference annotations describe at least one of a plurality of tissue or cellular characteristic categories for one or more frames in the set. Each frame in the set is processed using the trained model to generate model predictions. The model predictions describe at least one of the tissue or cellular characteristic categories for the processed frame. Performance of the trained model is validated based on determining a degree of association between the reference annotations and the model predictions for each frame and/or across all frames in the set of frames.Type: GrantFiled: November 10, 2022Date of Patent: February 27, 2024Assignee: PathAI, Inc.Inventors: Harsha Vardhan Pokkalla, Hunter L. Elliott, Dayong Wang, Benjamin P. Glass, Ilan N. Wapinski, Jennifer K. Kerner, Andrew H. Beck, Aditya Khosla, Sai Chowdary Gullapally, Ramprakash Srinivasan
-
Publication number: 20230329541Abstract: The present disclosure describes devices and methods for treating disorders in a hollow body organ by ablating the tissue therein. At least one set of bipolar electrodes is deployed in the hollow body organ to contact the inner wall of the organ. In the deployed position, each positive electrode is positioned in a location substantially opposite each negative electrode. The tissue contact areas of the positive and negative electrodes are substantially the same and the electrodes are separated from one another by a distance of at least 10 times the width of each of the electrodes. The electrodes thereby produce lesions that are substantially identical to one another and also similar to those produced with monopolar electrodes. The electrodes are used to produce an ablation pattern that can electrically isolate regions of the hollow body organ, thereby treating the disorder(s).Type: ApplicationFiled: September 26, 2022Publication date: October 19, 2023Inventors: Roger A. STERN, Jerome JACKSON, Benjamin WANG, Omry BEN-EZRA, Itzhak AVNERI, Lior AVNERI
-
Publication number: 20230285072Abstract: Systems, devices, and methods to treat a urinary bladder are disclosed. An expandable member is introduced and expanded in the urinary bladder to appose one or more elongate conductors on the outer surface of the expandable member against the inner wall of the urinary bladder. The one or more elongate conductors are used to create a predetermined pattern of electrically isolated tissue regions having reduced electrical propagation such that electrical propagation through the urinary bladder as a whole is reduced. A mucus layer may be removed from the inner bladder wall prior to the ablation. Ablation may be regulated by impedance measurement with the one or more elongate conductors. The urinary bladder may be filled with a fluid to facilitate the impedance measurement.Type: ApplicationFiled: November 18, 2022Publication date: September 14, 2023Inventors: Omry BEN-EZRA, Itzhak AVNERI, David STASKIN, Roger A. STERN, Jerome JACKSON, Benjamin WANG
-
Publication number: 20230283249Abstract: In certain examples, methods and semiconductor structures are directed to a switching (power) amplification circuit, including resonance circuitry to resonate at a frequency associated with at least one of a plurality of different selectable resonance frequencies. The switching amplification circuit is configured to deliver power to one or multiple loads while the switching amplifier circuit is operating based on one or more of the selectable resonance frequencies.Type: ApplicationFiled: February 20, 2023Publication date: September 7, 2023Inventors: Juan Rivas-Davila, Jiale Xu, Kawin Surakitbovorn, Benjamin Wang, Mark A. Cappelli
-
Patent number: 11718929Abstract: The present invention relates generally to the field of making novel antigen binding domains against infectious diseases. The present invention also relates to novel CARs that utilize the novel antigen binding domains as an extracellular element. The present invention also relates to use of the novel antigen binding domains as therapeutic agents.Type: GrantFiled: July 19, 2021Date of Patent: August 8, 2023Inventors: Benjamin Wang, Gusti Zeiner
-
Patent number: 11648277Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE) combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. These RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell. Such CAR T-cells with transgene payloads can be combined with the administration of other molecules, e.g., other therapeutics such as anticancer therapies.Type: GrantFiled: April 11, 2022Date of Patent: May 16, 2023Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Scott Dylla, Gusti Zeiner
-
Publication number: 20230128385Abstract: Methods and compositions for delivering a payload at TnMUC1 positive cancer cells. Anti-TnMUC1 CARs and transgene payloads can be engineered into immune cells so that the transgene payload is expressed and delivered at desired times from the immune cell. Such anti-TnMUC1 CAR T-cells with transgene payloads can be combined with the administration of other molecules, e.g., other therapeutics such as anticancer therapies.Type: ApplicationFiled: September 21, 2022Publication date: April 27, 2023Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner, Albert Gacerez, Eytan Herzig
-
Patent number: 11607513Abstract: A suction device for use with a medical device may include a suction device body and an extension. The suction device body may include a first lumen positioned therein and including a plurality of holes. The extension may include a second lumen positioned therein and may be coupled to the suction device body and configured to facilitate connection of the suction device body to a suction line. The second lumen may be in communication with/open to the first lumen and the suction line may be adapted for connection to a pump configured to apply a negative pressure to the first and second lumens. The suction device may evacuate fluids and/or solids from a patient in an area proximate to the suction device.Type: GrantFiled: October 12, 2017Date of Patent: March 21, 2023Assignee: NEVAP, INC.Inventor: Benjamin Wang
-
Patent number: 11572566Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: GrantFiled: February 28, 2022Date of Patent: February 7, 2023Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20230028899Abstract: Tandem gene pairs are described in which the GC3 Content of one gene changes its level of expression, and changes the level of expression of the tandem gene. This gene control is called Mercury and can be used to control the expression level of a gene of interest. Mercury is used herein to reduce tonic signaling from chimeric antigen receptors by reducing the expression of a chimeric antigen receptor.Type: ApplicationFiled: October 18, 2021Publication date: January 26, 2023Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Patent number: 11535853Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: GrantFiled: March 14, 2022Date of Patent: December 27, 2022Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Patent number: 11530272Abstract: RNA Control Devices and/or destabilizing elements (DE) can regulate the expression of Chimeric Antigen Receptors (CARs) in eukaryotic cells. More specifically, DEs, RNA Control Devices, and/or side-CARs can be used with small molecule ligands to regulate the expression of Chimeric Antigen Receptors. These DE-CARs, Smart CARs (Smart=small molecule actuatable RNA trigger), Smart-DE-CARs, and/or Side-CARs can be used in the treatment of disease.Type: GrantFiled: December 21, 2017Date of Patent: December 20, 2022Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Patent number: 11497774Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), and RNA control devices, combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. RDEs can be combined with RNA control devices to make RDEs that include ligand mediated control. These smart RDEs and other RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell.Type: GrantFiled: April 4, 2022Date of Patent: November 15, 2022Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner, Krista McNally
-
Publication number: 20220325288Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: ApplicationFiled: May 18, 2022Publication date: October 13, 2022Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Patent number: 11459572Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: GrantFiled: October 16, 2019Date of Patent: October 4, 2022Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner